Correlation Between Protalix Biotherapeutics and Fulcrum Therapeutics

Can any of the company-specific risk be diversified away by investing in both Protalix Biotherapeutics and Fulcrum Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Protalix Biotherapeutics and Fulcrum Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Protalix Biotherapeutics and Fulcrum Therapeutics, you can compare the effects of market volatilities on Protalix Biotherapeutics and Fulcrum Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Protalix Biotherapeutics with a short position of Fulcrum Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Protalix Biotherapeutics and Fulcrum Therapeutics.

Diversification Opportunities for Protalix Biotherapeutics and Fulcrum Therapeutics

-0.34

Correlation Coefficient

Protalix Biotherapeutics  Fulcrum Therapeutics

Very good diversification

The 3 months correlation between Protalix and Fulcrum is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Protalix Biotherapeutics and Fulcrum Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Fulcrum Therapeutics and Protalix Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Protalix Biotherapeutics are associated (or correlated) with Fulcrum Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Fulcrum Therapeutics has no effect on the direction of Protalix Biotherapeutics i.e., Protalix Biotherapeutics and Fulcrum Therapeutics go up and down completely randomly.

Pair Corralation between Protalix Biotherapeutics and Fulcrum Therapeutics

Considering the 90-day investment horizon Protalix Biotherapeutics is expected to generate 1.18 times less return on investment than Fulcrum Therapeutics. But when comparing it to its historical volatility, Protalix Biotherapeutics is 1.55 times less risky than Fulcrum Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Fulcrum Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  544.00  in Fulcrum Therapeutics on September 4, 2024 and sell it today you would lose (156.00) from holding Fulcrum Therapeutics or give up 28.68% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Protalix Biotherapeutics  vs.  Fulcrum Therapeutics

Protalix Biotherapeutics

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Protalix Biotherapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain essential indicators, Protalix Biotherapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Fulcrum Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Fulcrum Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain rather sound which may send shares a bit higher in January 2025. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders.

Pair Trading with Protalix Biotherapeutics and Fulcrum Therapeutics

The main advantage of trading using opposite Protalix Biotherapeutics and Fulcrum Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Protalix Biotherapeutics position performs unexpectedly, Fulcrum Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Fulcrum Therapeutics will offset losses from the drop in Fulcrum Therapeutics' long position.

The idea behind Protalix Biotherapeutics and Fulcrum Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sectors module to list of equity sectors categorizing publicly traded companies based on their primary business activities.